DR. JANET LUYU WANG NPI 1760629158

NPI Details

DR. Janet Luyu Wang is a hematology and oncology internal medicine in Santa Cruz, CA with 19 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Janet Luyu Wang NPI is 1760629158. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: BAYLOR COLLEGE OF MEDICINE
Graduation Year:2006

The provider's business location address is:

2850 COMMERCIAL CROSSING
SANTA CRUZ, CA
ZIP 95065-702
Phone: (831) 460-7355
Fax: (831) 460-7359

The NPI 1760629158 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, tocilizumab, 1 mg (HCPCS:J3262)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, golimumab, 1 mg, for intravenous use (HCPCS:J1602)
• Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0129)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Bcg live intravesical instillation, 1 mg (HCPCS:J9030)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Instillation of anti-cancer drug into bladder (HCPCS:51720)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Drawing of blood for a medical problem (HCPCS:99195)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Injection of drug or substance into vein (HCPCS:96374)

The enumeration date for this NPI number is 1/7/2009 and was last updated on 9/19/2012.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: